Placebo News and Research

RSS

Low dose aspirin is downgraded for preventing cardiovascular disease

A recent article posted in the Journal of the American Medical Association (JAMA) analyzed aspirin use to prevent cardiovascular disease (CVD) and colorectal cancer (CRC).

27 Apr 2022

Findings of the HITCH randomized clinical trial show lack of improvement in COVID-19 on temporary androgen suppression

Researchers investigated whether temporary androgen suppression by degarelix improved the clinical outcomes among male patients hospitalized with COVID-19.

27 Apr 2022

The effect of antidepressants on patient-reported health-related quality of life

A new study published in PLoS ONE aimed to investigate the effect of using antidepressant medications on the HRQoL of patients with depression.

27 Apr 2022

Moderate fitness levels produce significantly larger immune response in breast cancer survivors

A new study in breast cancer survivors has found that chemotherapy, while a critical part of breast cancer therapy, may also have some lasting dampening effects on natural immunity, but moderate fitness improvements can offer some protection against this effect.

26 Apr 2022

Phase I/II trials of new paratyphoid vaccine begin in Oxford

The University of Oxford in collaboration with the University of Maryland School of Medicine has begun recruiting for a Phase I/II trial of a new paratyphoid vaccine in human volunteers in Oxford - with first vaccinations taking place today (Tuesday).

26 Apr 2022

The impact of leronlimab on CCR5 surface cell levels during long COVID

The researchers assessed the impact of long COVID-19 on C-C chemokine receptor-5 (CCR5) and immunosuppression.

26 Apr 2022

Study shows combined benefit of three public health interventions for preventing invasive cancers

A new study published in Frontiers in Aging found that a combination of high-dose vitamin D, omega-3s, and a simple home strength exercise program (SHEP) showed a cumulative reduction by 61% in cancer risk in healthy adults aged 70 or older.

25 Apr 2022

Monoclonal-antibody combination AZD7442 prevents COVID-19

In a recent study published in The New England Journal of Medicine, the researchers examined the monoclonal-antibody combination AZD7442 to prevent coronavirus disease 2019 (COVID-19).

25 Apr 2022

Impact of COVID-19 vaccination on anti-nucleocapsid antibody levels

Anti-N antibodies may have lower sensitivity in mRNA-1273-vaccinated individuals who were previously infected with SARS-CoV-2.

24 Apr 2022

An abnormally suppressed immune system may be to blame in some cases of long COVID-19

A UCLA-led team of researchers studying the effect of the monoclonal antibody Leronlimab on long COVID-19 may have found a surprising clue to the baffling syndrome, one that contradicts their initial hypothesis.

22 Apr 2022

Study assesses whether early targeted treatment of patent ductus arteriosus improves outcomes in extreme preterm babies

A randomized controlled trial evaluates if selective early treatment of patent ductus arteriosus reduces death or bronchopulmonary dysplasia at 36 weeks in extreme preterm babies.

22 Apr 2022

Why cheap, older drugs that might treat covid never get out of the lab

In March 2020, Dr. Joseph Vinetz left the contemplative world of his Yale University infectious-disease laboratory and plunged into the covid ward at Yale New Haven Hospital, joining an army of health care workers who struggled to treat the deadly viral disease.

19 Apr 2022

New research on immune correlates for Janssen Ad26.Cov2.S COVID vaccine

ENSEMBLE data was used to evaluate three immune markers as correlates of protection following a single dose of Ad26.COV2.S vaccine.

18 Apr 2022

New study paves the way for first drug treatment for sleep apnea

A new University of Gothenburg study has paved the way for the first drug treatment for sleep apnea. Compared to before receiving the treatment, breathing pauses decreased with on average more than 20 per hour for patients given the drug.

15 Apr 2022

New drug shows promise in treating a movement disorder associated with Huntington's disease

A new drug has proven beneficial in treating a movement disorder commonly associated with Huntington's disease, according to a recent international study led by UTHealth Houston researcher Erin Furr Stimming, MD, who served as principal investigator on behalf of the KINECT-HD Huntington Study Group.

13 Apr 2022

Parallel approach to vaccine trials can lead to faster and more accurate assessment

Some of Rutgers' top health researchers are calling for a change in our approach to developing COVID-19 vaccines, and vaccines to fight future pandemics, to incorporate both conventional and challenge trails.

12 Apr 2022

NVX-CoV2373 vaccine found to induce functional SARS-CoV-2-specific T cell responses

In a recent study researchers evaluated the T cell responses elicited by full-length severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein vaccine NVX-CoV2373.

12 Apr 2022

Drug used to treat lung cancer could help improve survival rates for bladder cancer patients

Scientists from the University of Sheffield have discovered a drug already used to treat lung cancer could help to improve survival rates for bladder cancer patients.

11 Apr 2022

New study reveals oral opaganib's potent in vitro activity against Omicron

RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced study results in which opaganib (ABC294640), a leading oral drug candidate for hospitalized patients with moderate to severe COVID-19, was observed to have potent in vitro efficacy against the Omicron SARS-CoV-2 variant, while maintaining host cell viability.

11 Apr 2022

Safety profile of colchicine in COVID-19 patients

Researchers evaluated the use of colchicine in COVID-19 patients.

11 Apr 2022

Placebo News and Research

Low dose aspirin is downgraded for preventing cardiovascular disease

Findings of the HITCH randomized clinical trial show lack of improvement in COVID-19 on temporary androgen suppression

The effect of antidepressants on patient-reported health-related quality of life

Moderate fitness levels produce significantly larger immune response in breast cancer survivors

Phase I/II trials of new paratyphoid vaccine begin in Oxford

The impact of leronlimab on CCR5 surface cell levels during long COVID

Study shows combined benefit of three public health interventions for preventing invasive cancers

Monoclonal-antibody combination AZD7442 prevents COVID-19

Impact of COVID-19 vaccination on anti-nucleocapsid antibody levels

An abnormally suppressed immune system may be to blame in some cases of long COVID-19

Study assesses whether early targeted treatment of patent ductus arteriosus improves outcomes in extreme preterm babies

Why cheap, older drugs that might treat covid never get out of the lab

New research on immune correlates for Janssen Ad26.Cov2.S COVID vaccine

New study paves the way for first drug treatment for sleep apnea

New drug shows promise in treating a movement disorder associated with Huntington's disease

Parallel approach to vaccine trials can lead to faster and more accurate assessment

NVX-CoV2373 vaccine found to induce functional SARS-CoV-2-specific T cell responses

Drug used to treat lung cancer could help improve survival rates for bladder cancer patients

New study reveals oral opaganib's potent in vitro activity against Omicron

Safety profile of colchicine in COVID-19 patients

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News